Related Experiment Video
Updated: Dec 7, 2025
Mouse Models of Periventricular Leukomalacia
Published on: May 18, 2010
Intranasal IL-4 Administration Alleviates Functional Deficits of Periventricular Leukomalacia in Neonatal Mice
Lin-Chao Yu1,2,3,4,5, Jing-Kun Miao1,2,3,6, Wei-Bin Li7
1Department of Neonatology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Insights
Intranasal interleukin-4 (IL-4) administration shows promise for treating periventricular leukomalacia (PVL) in premature infants by improving myelination and reducing neurological deficits. This noninvasive approach targets microglial polarization for potential therapeutic benefits.
Area of Science:
- Neuroscience
- Immunology
- Neonatal Medicine
Background:
- Periventricular leukomalacia (PVL) is a primary cause of brain injury in premature infants, with no current effective treatments.
- Microglial polarization is implicated in brain injury and recovery, with Interleukin-4 (IL-4) known to modulate immune responses.
- Intranasal drug delivery offers a noninvasive route for therapeutic agents targeting the central nervous system.
Purpose of the Study:
- To investigate the potential of intranasal administration of IL-4 as a therapeutic strategy for PVL.
- To evaluate the neuroprotective effects of IL-4 in a mouse model of PVL.
- To explore the underlying mechanisms of IL-4's action on microglial polarization and myelination.
Main Methods:
- A severe acute hypoxia (SAH) protocol was used to establish a PVL mouse model.
- Exogenous IL-4 was administered intranasally to assess its therapeutic effects.
- Neurological deficits, microglial activation (Iba1+), myelination markers (NG2, MAG, MBP), and protein levels were analyzed using functional studies, immunohistochemistry, Western blotting, and electron microscopy.
Main Results:
- Hypoxia induced microglial activation, reduced myelin gene/protein expression, and caused neurological deficits.
- Intranasal IL-4 administration partially inhibited microglial activation, enhanced myelination, and alleviated neurological deficits.
- IL-4 treatment promoted microglial polarization from M1 to M2 phenotype via IL-4Ra, suggesting a mechanism for improved myelination.
Conclusions:
- Intranasal IL-4 administration effectively improves myelination and reduces functional deficits in a hypoxia-induced PVL model.
- This noninvasive therapeutic strategy holds promise for treating PVL in premature infants.
- Further mechanistic studies are warranted to fully elucidate the therapeutic potential of intranasal IL-4 for PVL.
Abstract:
Background: Periventricular leukomalacia (PVL) is the major form of brain injury in premature infants. Currently, there are no therapies to treat PVL. Several studies suggested that polarization of microglia, a resident macrophage-like immune cell in the central nervous system, plays a vital role in brain injury and recovery. As an important mediator of immunity, interleukin-4 (IL-4) has critical effects on many immune cells, such as astrocytes and microglia. Increasing evidence shows that IL-4 plays a well-established role in attenuating inflammation in neurological disorders. Additionally, as a noninvasive and highly effective method, intranasal drug administration is gaining increasing attention. Therefore, in our study, we hypothesized that intranasal IL-4 administration is a promising strategy for PVL treatment. Methods: The therapeutic effects of IL-4 on neuroprotection were evaluated using a Control group, Hypoxia group, and Hypoxia + IL-4 treatment group. The PVL mouse model was established by a severe acute hypoxia (SAH) protocol. Exogenous IL-4 was intranasally administered to investigate its neuroprotective effects. A functional study was used to investigate neurological deficits, immunohistochemical technology and Western blotting were used to detect protein levels, and electron microscopy was used to evaluate myelination. Results: The results suggested that hypoxia stimulated Iba1+ microglial activation, downregulated myelin-related gene (NG2, MAG, and MBP) expression, reduced MBP protein levels, and caused neurological deficits. However, the intranasal administration of exogenous IL-4 partially inhibited Iba1+ microglial activation, improved myelination, and alleviated neurological deficits. The mechanistic study showed that IL-4 improved myelination possibly through the IL-4Ra-mediated polarization of microglia from the M1 phenotype to the M2 phenotype. Conclusion: In summary, our findings demonstrated that the intranasal administration of exogenous IL-4 improves myelination and attenuates functional deficits in a hypoxia-induced PVL model. Intranasal IL-4 administration may be a promising strategy for PVL treatment, for which further mechanistic studies are urgent.
